Antigenics’ Oncophage Approved In Russia, First Therapeutic Cancer Vaccine To Enter Marketplace

The biologic will launch this summer at a price in the lower range of $50,000-$100,000/patient/year, the typical cost of new cancer drugs in Russia, firm tells “The Pink Sheet” DAILY.